Movement Alert｜Iovance Biotherapeutics, Inc. Rises 10.03% in Regular Trading, Q2 Earnings Beat Fuels Continued Upward Momentum

Market Focus

Aug 20

On August 20, Iovance Biotherapeutics, Inc. rose 10.03% in regular trading, reaching $7.735/share with turnover of $104 million. The stock continues to trade in a post-earnings upward channel following its strong Q2 results released on August 6.

The company reported Q2 EPS of $(0.11), beating analyst estimates of $(0.14), while revenue reached a record $99.313 million, significantly surpassing the consensus estimate of $87.832 million. The combination of narrower-than-expected losses and substantial revenue outperformance reflects accelerating commercial traction for the company's autologous tumor infiltrating lymphocyte therapy platform. Iovance is a commercial-stage biotechnology company focused on cell therapies for metastatic melanoma and other solid tumor cancers, with its lead product Amtagvi driving revenue growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1148470279"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148470279\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148470279?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 01:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148470279","market":"us","top_or_hot":-1,"title":"Movement Alert｜Iovance Biotherapeutics, Inc. Rises 10.03% in Regular Trading, Q2 Earnings Beat Fuels Continued Upward Momentum","media":"Market Focus","content":"<p><p>On August 20, Iovance Biotherapeutics, Inc. rose 10.03% in regular trading, reaching $7.735/share with turnover of $104 million. The stock continues to trade in a post-earnings upward channel following its strong Q2 results released on August 6.</p><p>The company reported Q2 EPS of $(0.11), beating analyst estimates of $(0.14), while revenue reached a record $99.313 million, significantly surpassing the consensus estimate of $87.832 million. The combination of narrower-than-expected losses and substantial revenue outperformance reflects accelerating commercial traction for the company's autologous tumor infiltrating lymphocyte therapy platform. Iovance is a commercial-stage biotechnology company focused on cell therapies for metastatic melanoma and other solid tumor cancers, with its lead product Amtagvi driving revenue growth.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Iovance Biotherapeutics, Inc. Rises 10.03% in Regular Trading, Q2 Earnings Beat Fuels Continued Upward Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Iovance Biotherapeutics, Inc. Rises 10.03% in Regular Trading, Q2 Earnings Beat Fuels Continued Upward Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 01:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, Iovance Biotherapeutics, Inc. rose 10.03% in regular trading, reaching $7.735/share with turnover of $104 million. The stock continues to trade in a post-earnings upward channel following its strong Q2 results released on August 6.</p><p>The company reported Q2 EPS of $(0.11), beating analyst estimates of $(0.14), while revenue reached a record $99.313 million, significantly surpassing the consensus estimate of $87.832 million. The combination of narrower-than-expected losses and substantial revenue outperformance reflects accelerating commercial traction for the company's autologous tumor infiltrating lymphocyte therapy platform. Iovance is a commercial-stage biotechnology company focused on cell therapies for metastatic melanoma and other solid tumor cancers, with its lead product Amtagvi driving revenue growth.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1148470279","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148470279","pubTimestamp":1787159634,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, Iovance Biotherapeutics, Inc. rose 10.03% in regular trading, reaching $7.735/share with turnover of $104 million. The stock continues to trade in a post-earnings upward channel...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"走势警报|Iovance Biotherapeutics, Inc. 常规交易中上涨 10.03%，第二季度盈利超出预期，推动持续上涨势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"On August 20, Iovance Biotherapeutics, Inc. rose 10.03% in regular trading, reaching $7.735/share with turnover of $104 million. The stock continues to trade in a post-earnings upward channel following its strong Q2 results released on August 6.The company reported Q2 EPS of $(0.11), beating analyst estimates of $(0.14), while revenue reached a record $99.313 million, significantly surpassing the consensus estimate of $87.832 million. The combination of narrower-than-expected losses and substantial revenue outperformance reflects accelerating commercial traction for the company's autologous tumor infiltrating lymphocyte therapy platform. Iovance is a commercial-stage biotechnology company focused on cell therapies for metastatic melanoma and other solid tumor cancers, with its lead product Amtagvi driving revenue growth.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}